Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in the Treatment of Patients with Recurrent Platinum-resistant Ovarian Cancer (Sunrise Trial): a Single-Arm, Exploratory Study

NCT06600841 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT06600841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06600841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in the Treatment of Patients with Recurrent Platinum-resistant Ovarian Cancer (Sunrise Trial): a Single-Arm, Exploratory Study
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2024
Completion date
October 1, 2028
Enrollment
37 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunotherapy, platinum-resistant ovarian cancer (proc)